Cannabis legalization for recreational purposes
In response to the high use rates among Canadians ― particularly among youth ― the federal government has committed to legalizing the recreational use of cannabis by July 2018.
Recommending a public health approach
In legalizing cannabis, the federal government must focus on protecting Canadians and reducing any potential impact on health — in particular for children and youth.
submission to the federal Task Force on Cannabis Legalization and Regulation, the CMA recommends a broad public health approach that would focus on:
- preventing drug dependence and addiction;
- increasing availability of assessment, counselling and treatment services for those who wish to stop using; and
- increasing the safety for those who are using through harm reduction programs and awareness.
In June 2017, the CMA publicly supported the release of
Canada’s Lower-Risk Cannabis Use Guidelines, which provide 10 science-based recommendations to enable cannabis users to reduce their health risks.
submission to the House of Commons’ Standing Committee on Health in August 2017, the CMA reinforced the need for a public health approach in the legalization of cannabis for recreational purpose.
Regulating cannabis: protecting Canadians’ health
In regulating cannabis, Canadians must be protected from misleading claims. Despite being regulated by Health Canada, health products containing cannabis undergo different levels of scrutiny compared to prescription drugs. Many consumers may not be aware of this discrepancy.
In its January 2018
submission to Health Canada, the CMA recommends that government and health professionals — not cannabis producers or distributors — design cannabis labeling and packaging to emphasize the health risks associated with consumption.
Like tobacco and cigarettes, cannabis packaging and labeling provide an opportunity to raise awareness of the health, social and economic harms of use, especially in youth.
Cannabis for medical purposes
Government regulation currently permits the use of cannabis for medical purposes. With the legalization of cannabis in October 2018, the federal government has committed to reviewing the medical marijuana system within the next five years.
The CMA supports this review. While the CMA recognizes that some individuals suffering from terminal illness or chronic disease may obtain relief with cannabis, the CMA remains concerned about the lack of clinical research, guidance and regulatory oversight for cannabis as a potential medical intervention.
Many physicians feel uncomfortable prescribing a substance that hasn’t undergone the same regulatory review processes required for all other prescription medicines. These processes are designed to protect patients and to provide critical information to prescribing physicians, such as clinical indications, dosages, and potential interactions with other medications. This information is currently limited for cannabis.
Learn more about cannabis and the CMA
For more information on the CMA’s work on cannabis, please contact